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Abstract
Aims/hypothesis We explored the potential adverse effects
of pro-atherogenic oxidised LDL-cholesterol particles on
beta cell function.
Materials and methods Isolated human and rat islets and
different insulin-secreting cell lines were incubated with
human oxidised LDL with or without HDL particles. The
insulin level was monitored by ELISA, real-time PCR and a
rat insulin promoter construct linked to luciferase gene
reporter. Cell apoptosis was determined by scoring cells
displaying pycnotic nuclei.
Results Prolonged incubation with human oxidised LDL
particles led to a reduction in preproinsulin expression
levels, whereas the insulin level was preserved in the
presence of native LDL-cholesterol. The loss of insulin
production occurred at the transcriptional levels and was
associated with an increase in activator protein-1 transcrip-
tional activity. The rise in activator protein-1 activity
resulted from activation of c-Jun N-terminal kinases
(JNK, now known as mitogen-activated protein kinase
8 [MAPK8]) due to a subsequent decrease in islet-brain 1
(IB1; now known as MAPK8 interacting protein 1) levels.
Consistent with the pro-apoptotic role of the JNK pathway,
oxidised LDL also induced a twofold increase in the rate of
beta cell apoptosis. Treatment of the cells with JNK
inhibitor peptides or HDL countered the effects mediated
by oxidised LDL.
Conclusions/interpretation These data provide strong evi-
dence that oxidised LDL particles exert deleterious effects
in the progression of beta cell failure in diabetes and that
these effects can be countered by HDL particles.
Keywords Apoptosis . Diabetes . HDL . Insulin . JNK
pathway .MAPK . Oxidised LDL . Pancreatic beta cells
Abbreviations
AP1 activator protein-1
AP1Luc luciferase reporter construct driven by multi-
merised AP1 consensus sequences
Bcl2 B-cell leukaemia/lymphoma 2
GST glutathione S-transferase
IB1 islet brain 1
JNK c-Jun N-terminal kinases
Luc luciferase reporter construct
MAPK8 mitogen-activated protein kinase 8
Rip rat insulin II promoter
RIPE rat insulin promoter element
RipLuc rip linked to the luciferase reporter
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Introduction
A decline in the number of insulin-producing beta cells
and/or their intrinsic ability to produce and/or secrete
insulin contributes to the pathophysiology of type 2
diabetes [1]. It is now accepted that this beta cell
inadequacy results in part from oxidative stress due to
adverse effects of chronic elevation of glucose and free or
non-esterified fatty acids [2–4]. Among the major mecha-
nisms that have been associated with oxidative stress, is
induction of the c-Jun N-terminal kinases (JNK, now
known as mitogen-activated protein kinase 8 [MAPK8])
signalling pathway, leading to activation of activator
protein-1 (AP1) transcriptional factors complex [5, 6].
Suppression of this pathway prevents the loss of preproin-
sulin gene expression and apoptosis [7, 8].
Islet-brain 1/JNK-interacting protein 1 (IB1; now known
as MAPK8 interacting protein 1) is a mammalian scaffold
protein involved in the regulation of the JNK pathway [9–
11]. One of the outcomes of this regulation is to prevent the
activation of c-Jun (now known as JUN or Jun oncogene), a
transcription factor included in the AP1 transcriptional
complex that directly represses production of insulin and
induces beta cell apoptosis [11–14]. Reduction in IB1
content diminishes preproinsulin mRNA levels and renders
the cells more sensitive to stress-induced programmed death
[11, 15, 16]. The importance of IB1 levels in beta cells has
been confirmed in human diabetes. A missense mutation
(S59N) in the gene encoding IB1 has been found to co-
segregate with diabetes in a French family with a monogenic
form of type 2 diabetes. Ex vivo, this mutation reduces the
stability of IB1, leading to decreased insulin promoter
activity and acceleration of the rate of cell apoptosis [11, 17].
Elevated levels of oxidised LDL-cholesterol, together
with low HDL-cholesterol, are typical symptoms of
diabetic dyslipidaemia and risk factors for prediabetic and
diabetic patients to develop cardiovascular diseases [18–
20]. Oxidised LDL is produced in the subendothelial space
and is taken up by resident macrophages via scavenger
receptors [21–23], leading to their transformation into foam
cells. A recent report shows that beta cells express scavenger
receptor class B, member 1 and CD36, two scavenger
receptors for oxidised LDL, and that incubation of beta cells
with oxidised LDL causes a decline in specialised tasks
including insulin synthesis [24]. Oxidised LDL can induce
oxidative stress in several tissues, including activation of
the JNK signalling pathway and AP1 transcriptional
activity [25–27]. In view of these data, we postulated that
JNK signalling is implicated in the alteration of insulin
production and cell survival caused by oxidised LDL.
Herein, we provide evidence that oxidised LDL, but not
native LDL, exerts deleterious effects on insulin levels and
beta cell survival by activating the JNK pathway. Selective
inhibition of this pathway with peptide inhibitors or
incubation with human HDLs countered the effects medi-
ated by oxidised LDL.
Materials and methods
Lipoprotein preparation Blood was collected from healthy
donors. Plasma LDL fractions were isolated by sequential
ultracentrifugation (LDL density, 1.063) and dialysed
against PBS. Samples were analysed by SDS-PAGE to
assess the integrity of apolipoproteins and the purity of the
different fractions. The lipoprotein preparations contained
less than 0.112 units of endotoxin/μmol cholesterol as
determined by the kinetic chromogenic technique (Endotell,
Allschwil, Switzerland). Oxidation of LDL particles (at
1 mg/ml protein concentration in PBS) was performed by
incubation with 5 μmol/l CuSO4 at 37°C for 18 h. The
oxidation reaction was stopped at 4°C for 30 min by adding
300 μmol/l EDTA and by thorough dialysis against PBS
and subsequently against either DMEM or RPMI medium
without fetal calf serum. The oxidation reaction was
verified by determining the lipid peroxide content as
previously described [28].
Preparation and culture of islets Rat islets were isolated
from the pancreas of male Sprague–Dawley rats weighing
250–350 g by ductal injection of collagenase. The
purification of islets was conducted as described [29].
Isolated human islets were obtained from the Cell Isolation
and Transplantation Center (islets for research distribution
programme) of the Geneva University Hospitals. Islets were
cultured in CMRL-1066 supplemented with 10% fetal
bovine serum (Mediatech, Herndon, VA, USA) in a 5%
CO2 humidified atmosphere at 37°C.
Cell culture, transient transfection and plasmids The
insulin-secreting cell lines (MIN6 and INS-1E) and rat
isolated islets were maintained as previously described [30].
Transient transfection experiments were performed using a
kit (Effectene Transfection Reagent kit; Qiagen, Basel,
Switzerland) as reported [30]. The following plasmids were
used for the transfection assays: a 600-base pair sequence
of the rat insulin II promoter (Rip) cloned upstream of the
firefly luciferase gene [11]; rat insulin promoter element
(RIPE)3Luc [11]; and a luciferase reporter construct (Luc)
driven by multimerised AP1 consensus sequences
(AP1Luc). The latter two are firefly luciferase reporter
constructs corresponding to five copies of the (RIPE)3
binding site (containing the E elements) and to four copies
of the canonical AP1-responsive elements inserted up-
stream of the TATA minimal promoter, respectively.
Luciferase activities from the firefly and the renilla from
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the pRL-SV40 vector (Promega, Wallisellen, Switzerland)
were measured using an assay system (Dual-Luciferase
Reporter; Promega).
Measurement of insulin content Cells (5×105) were plated
in 24-well dishes and cultured in the presence of vehicle,
native and oxidised LDL for 72 h. Afterwards, the cells
were washed three times with a modified KRB/bicarbonate-
HEPES buffer (140 mmol/l NaCl, 3.6 mmol/l KCl,
0.5 mmol/l NaH2PO4, 0.5 mmol/l MgSO4, 1.5 mmol/l
CaCl2, 2 mmol/l NaHCO3, 10 mmol/l HEPES, 0.1% bovine
serum albumin) containing 2 mmol/l glucose. Insulin
contents were extracted with acid/ethanol solution and
measured by ELISA (Linco Research, St Charles, MO,
USA) as recommended by the manufacturer’s protocol.
Apoptosis assay Apoptosis was determined by scoring cells
displaying pycnotic nuclei visualised with Hoechst 33342
(Invitrogen, Basel, Switzerland) [28].
Protein kinase assay The preparation of whole-cell protein
extracts and the kinase assays were conducted as previously
described [8]. Briefly, cell extracts were incubated for 1 h at
room temperature with 1 μg glutathione S-transferase
(GST)-Jun (amino acids 1–89) and 10 μl glutathione-
agarose beads (Sigma-Aldrich, St-Gallen, Switzerland).
After several washings, the beads were supplemented with
JNK inhibitor or TAT (control) peptides for 20 min [8]. The
JNK inhibitor peptides used were the JNK binding domain
of IB1, which was coupled covalently to an N-terminal ten-
amino acid carrier peptide derived from the HIV-TAT48–57
sequence [8]. The retro-inverso D-enantiomer TAT and JNK
inhibitor peptides (Auspep PLT, Melbourne, VIC, Australia)
[8] were a gift from C. Bonny (S. A. Xigen, Lausanne,
Switzerland). Phosphorylation of substrate proteins was
examined after overnight exposition of polyacrylamide
gels to autoradiography; gel quantifications were accom-
plished by Phosphor-Imager analysis (Molecular Imager
FX; Bio-Rad Laboratories, Basel, Switzerland).
Nuclear protein extracts preparation and electromobility
shift assays Nuclear protein extracts and binding reaction
were conducted exactly as previously reported [30]. The
primers used as labelled probe were: AP1: sense: 5′-CG
CTTGATGAGTCAGCCGGAA-3′ and antisense 5′-GGC
TGACTCATCAAGCG-3′.
Western blotting, total RNA preparation and real-time
PCR For western blotting, the cell extracts were separated
by SDS-PAGE and blotted on nitrocellulose membranes.
The proteins were detected using specific antibodies and
were visualised by chemiluminescence using horseradish
peroxidase-coupled secondary antibodies. Total RNA from
insulin-secreting cell lines and pancreatic islets was
extracted using an RNA purification kit (Ambion, Austin,
TX, USA) according to the manufacturer’s protocol.
Reverse transcription reactions were performed as previous-
ly described [30]. Real-time PCR assays were carried out on
a real-time PCR detection system (MyiQ Single-Colour;
Bio-Rad) using iQ SYBR Green Supermix (Bio-Rad), with
100 nmol/l primers, 1 μl of template per 20 μl of PCR and
an annealing temperature of 59°C. Melting curve analyses
were performed on all PCRs to rule out non-specific
amplification. Reactions were carried out in triplicate.
Primer sequences for PCR were as follows: mouse and
human insulin, sense 5′-TGGCTTCTTCTACACACCCA-3′,
antisense 5′-TCTAGTTGCAGTAGTTCTCCA-3′; mouse and
human tubulin, sense 5′-GGAGGATGCTGCCAATAACT-3′,
antisense 5′-GGTGGTGAGGATGGAATTGT-3′; rat and
mouse Ib1, sense 5′-AGTGTCCAGCTTCCCTTGTC-3′,
antisense 5′-TTACTGTGGCCCTCTCCTTG-3′; human
IB1, sense 5′-ATCAGCCTGGAGGAGTTTGA-3′, antisense
5′-AGGTCCATCTGCAGCATCTC-3′; human FOS, sense
5′-TGATACACTCCAAGCGGAGAC-3′, antisense 5′-CCC
AGTCTGCTGCATAGAAGG-3′; mouse ribosomal phospho-
protein P0 gene, sense 5′-ACCTCCTTCTTCCAGGCTTT-3′,
antisense 5′-CCACCTTGTCTCCAGTCTTT-3′; mouse B-
cell leukaemia/lymphoma 2 (Bcl2), sense: 5′-CTCCCGATT
CATTGCAAGTT-3′, antisense 5′-TCTACTTCCTCCG
CAATGCT-3′.
Statistical analyses Data are expressed as means±SEM.
Unpaired two-tailed Student’s t test was used to compare
groups.
Results
Oxidised LDL particles reduce insulin expression at the
transcript level We first investigated the effects of oxidised
LDL particles on insulin production. In vitro oxidisation of
LDL-cholesterol particles by copper has been previously
shown to generate similar changes in LDL particles to those
occurring in endothelial cells, including lipid peroxidation
and extensive hydrolysis of phosphatidylcholine [31]. For
this reason, we chose to oxidise LDL particles by copper, as
performed in many reports [24, 32, 33], in order to evaluate
the effects of oxidised LDL on beta cells. Insulin contents
were measured from MIN6 cells cultured with different
concentrations of freshly purified oxidised LDL-cholesterol
particles. The results show that oxidised LDL reduced
insulin content in a dose-dependent manner, whereas native
LDL did not affect insulin expression (Fig. 1a). Similar
results were obtained in INS-1E cells (data not shown) and
are consistent with the data of a previous study showing
1306 Diabetologia (2007) 50:1304–1314
that native LDL at cholesterol concentrations between 1.6
and 3.1 mmol/l has no effect on beta cell survival and
function [28]. To evaluate the effects of modified LDL for
the following experiments, we chose to incubate the cells at
an oxidised LDL concentration of 2 mmol/l. Under these
conditions, as previously reported [24], we found that the
decrease in insulin content was associated with a loss in
preproinsulin mRNA levels (Fig. 1b). These oxidised LDL-
mediated effects also occurred at 48 h (data not shown) of
culture and were observed in isolated human and rat islets
(Fig. 1b), as well as in the insulin-secreting cell lines MIN6
(Fig. 1b) and INS-1 (data not shown).
Oxidised LDL diminishes the expression of insulin at the
promoter level We next assessed the hypothesis that
oxidised LDL-mediated effects on insulin expression
occurs at transcriptional levels. For this purpose, a 600-
base pair fragment of rat insulin II promoter (Rip) linked to
the luciferase reporter (RipLuc) construct was transiently
transfected in INS-1E cells [11]. While culture of the
transfected cells with native LDL did not significantly
modify the luciferase activity of RipLuc, oxidised LDL
caused a drastic decrease in production of the reporter gene
(Fig. 2a). The activity of the Rip is dependent for a large
part on an enhancer region (5′-GCCATCTG-3′), which is
referred to as insulin control element or E element [34, 35].
When multimerised and cloned downstream of a SV40
promoter, this region is capable of enhancing expression of
a luciferase gene from the (RIPE)3Luc construct [11, 13].
To verify whether the E element is responsible for the loss
of insulin expression, INS-1E cells transfected with this
heterologous promoter construct were cultured in the
presence of oxidised LDL. We found that incubation with
oxidised LDL but not with native LDL generated a twofold
decrease in the luciferase activity of (RIPE)3Luc (Fig. 2b).
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Fig. 1 Effects of oxidised LDL on insulin levels. a Insulin content
of MIN6 cells exposed for 72 h to vehicle (−), native LDL and
different concentrations of oxidised LDL-cholesterol particles. Data
(mean ± SEM) are representative of four independent experiments.
b Analysis of representative insulin mRNA levels by real-time PCR.
Total RNAwas isolated from MIN6 cells (grey bars), isolated rat islets
(striped bars) and isolated human islets (black bars) that had been
cultured for 72 h with different LDL preparations. Total RNA was
then subjected to real-time PCR to measure the preproinsulin and
β-tubulin (internal control) mRNA levels. Data from cells cultured
with vehicle (−) were set to 100%. Data are the mean ± SEM of three
independent experiments. ** p<0.01; *** p<0.001
Fig. 2 Effects of oxidised LDL on insulin reporter construct activity
in MIN6 cells. Vehicle (−), native and oxidised LDL-cholesterol
particle preparations were added to culture medium 2 h after
transfection. Exposure of cells to oxidised LDL led to a reduction of
(a) the luciferase activity of a 600-bp fragment of the rat insulin
promoter (RipLuc) and (b) the heterologous promoter activity
containing insulin control element (ICE) (RIPE)3Luc. The empty
pGL3basic (Luc) and the SV40Luc vectors were used as controls for
measuring the promoter activity of RipLuc and (RIPE)3Luc, respec-
tively. All luciferase activities were normalised using pRLSV40
renilla. Each experiment was performed at least three times in
triplicate. All values are expressed as per cent of SV40Luc activity in
cells cultured with vehicle (−). Results are mean ± SEM. *** p<0.001
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Introduction of a mutation in E elements [11] prevented the
loss of luciferase activity mediated by oxidised LDL (data
not shown). This indicates that the E element is responsible
for the loss of insulin expression.
Oxidised LDL induces JNK activity, increases AP1
transcriptional activity and downregulates expression of
Ib1 It is well documented that the E element of Rip binds the
basic helix loop helix transcription factors [34, 35]. Previous
reports have demonstrated that c-Jun, a component of the
AP1 transcriptional complex [36], can inhibit the E47 basic
helix loop helix factor, leading to inhibition of insulin
promoter activity [13, 14]. Interestingly, oxidised LDL led
to oxidative stress in various cell types [25, 27]. This
phenomenon involves activation of the JNK signalling
cascade and culminates in an increase in the activity of
AP1 transcriptional complexes due to an elevation of c-Jun
levels and its activity [25, 37, 38]. Based on these
observations, we hypothesised a possible increase in AP1
activity in cells cultured with oxidised LDL. To test this
assumption, we monitored AP1 activity by transiently trans-
fecting a luciferase reporter construct driven by multimerised
AP1 consensus sequences (AP1Luc). While no changes in
AP1Luc activity were observed in the presence of native LDL,
in cells cultured with 2 mmol/l oxidised LDL-cholesterol a
twofold increase in the luciferase activity of AP1Luc was
detected (Fig. 3). In addition, electromobility shift assay
experiments performed using the AP1 consensus sequence as
labelled probe revealed an increase in AP1 binding pattern in
nuclear extracts from cells cultured with oxidised LDL
(Electronic supplementary material [ESM] Fig. 1).
To determine whether the rise in AP1 activity was the
result of increased JNK activity, we measured JNK-
mediated phosphorylation of the target transcription factor
c-Jun. Total proteins from cells cultured with either
2 mmol/l of oxidised LDL or native LDL were incubated
with the c-Jun recombinant. Using extracts of cells treated
by oxidised LDL, kinase experiments show a time-
dependent increase in c-Jun phosphorylation (Fig. 4a,b).
As expected, the phosphorylation of c-Jun was efficiently
blocked by 5 μmol/l JNK inhibitor peptides [8] or by the
selective JNK inhibitor SP600125 (ESM Fig. 2). Phosphor-
ylation of c-Jun occurred with extracts of cells incubated
for 45 min and 72 h with oxidised LDL, whereas native
LDL did not induce any change in phosphorylation of
c-Jun. Phosphorylation of JNK is required for JNK to
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Fig. 3 Assessment of AP1 transcriptional activity in cells challenged
with oxidised LDL. MIN6 cells were transiently transfected with a
luciferase reporter construct driven by multimerised AP1 consensus
sequences (AP1Luc). Data are expressed as per cent of control
(activity of the construct in cells incubated with vehicle) and are the
mean ± SEM of three independent experiments. *** p<0.001
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Fig. 4 Effects of oxidised LDL (oxLDL) on JNK activity. a, bWhole-
cell extracts were prepared from cells incubated with 2 mmol/l
oxidised LDL or native LDL at the indicated times. JNK inhibitor
peptides (JNKi) (b), at a 5 μmol/l concentration, were added in cells
cultured with oxidised LDL (2 mmol/l). JNK solid-phase JNK assays
were performed with the lysates using GST-c-Jun as substrate. The
reaction was loaded on a polyacrylamide gel and γ-33P-phosphorylation
of the substrates (Phospho-c-Jun) was subsequently analysed. The gel
was stained with Coomassie blue to evaluate the loading of substrate
(GST-Jun). The results are representative of three independent experi-
ments. c, d Measurement of c-Jun and Fos expression levels by real-
time PCR. The mRNA levels of these genes were normalised against
β-tubulin and expression levels from cells cultured with vehicle were
set to 100%. Data are the mean ± SEM of four independent experiments.
*** p<0.001
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phosphorylate its substrates. Consistent with this, western
blotting experiments showed an increase in JNK activity in
cells exposed to oxidised LDL (Fig. 4a,b). Thus, these
results confirm that activation of JNK is induced by
oxidised LDL. To validate activation of the JNK signalling
cascade by oxidised LDL, expression of the c-Jun and Fos
genes was then quantified. The transcriptional activity of
the promoters of these two genes is positively regulated by
JNK [8]. Real-time PCR analysis showed a statistically
significant augmentation by 1.5- and threefold in Fos and
c-Jun mRNA levels, respectively, in MIN6 cells cultured
with oxidised LDL (Fig. 4c,d).
We next investigated whether JNK activation is respon-
sible for the loss of insulin production. Insulin-secreting
cells were incubated with oxidised LDL in the presence of
JNK inhibitor. Treatment of the cells with these peptides
prevented the decrease in preproinsulin mRNA and
(RIPE)3Luc promoter activity caused by oxidised LDL
(Fig. 5a,b). Prolonged exposure of cells to various stressors
has been shown to activate the JNK pathway in beta cells.
In some cases, this activation results from the decline of
IB1 levels [15, 16, 39]. This prompted us to evaluate the
expression of Ib1 in cells treated with the oxidised LDL
preparation. Western blotting showed a decrease in IB1
protein contents in MIN6 cells treated with oxidised LDL
for 72 h, whereas the content was unaffected at 45 min of
culture (Fig. 6a). Real-time PCR confirmed the reduction in
IB1 mRNA levels in isolated human and rat islets as well as
in MIN6 cells cultured with oxidised LDL for 72 h (ESM
Fig. 3).
Activation of the JNK pathway has often been associated
with an increase in beta cell programmed death [8, 15, 40].
We therefore tested the viability of insulin-secreting cells in
the presence of LDL-cholesterol preparations. As expected,
the rate of apoptosis of the cells cultured with 2 mmol/l
oxidised LDL-cholesterol for 72 h increased by threefold in
MIN6 cells and rat isolated islets, whereas the viability of
the cells incubated in the presence of native LDL was
unchanged (Fig. 6b). The rate of apoptosis was similar
when MIN6 cells were incubated either at 20 or at
10 mmol/l glucose. This result is in agreement with a
previous report showing that glucose did not render cells
more sensitive to the effects of LDL [28]. Co-treatment
with JNK inhibitors prevented the apoptosis of cells
mediated by oxidised LDL (Fig. 6c). Real-time PCR
experiments showed a reduction of Bcl2 expression
(Fig. 6d). This result is in agreement with the induction of
the apoptotic pathway by oxidised LDL as reported in
endothelial cells [41]. In contrast to early effects of oxidised
LDL on insulin levels, the viability of the cells cultured
with oxidised LDL for 48 h was apparently unchanged
(data not shown). This result indicates that the loss of
insulin expression induced by oxidised LDL probably
precedes programmed cell death.
Taken together, our results indicate that the effects of
oxidised LDL on insulin expression and beta cell survival
are linked to activation of the JNK signalling pathway
resulting from a decrease in IB1 contents.
HDL protects cells from oxidised LDL-induced loss of
insulin expression and death HDL has been described to
protect beta cells from cytokine- and LDL-mediated
apoptosis [28]. To assess the potential protective effects of
HDL on the decline of insulin expression and the induction
of cell death mediated by oxidised LDL, MIN6 cells and
isolated human islets were co-incubated with HDL and
LDL preparations. HDL at 1 mmol/l of cholesterol
concentration protected the cells from apoptosis (Fig. 7a)
Fig. 5 Effects of JNK inhibition on the loss of insulin expression
mediated by oxidised LDL. a JNK inhibitor (filled bars) or D-TAT
(open bars) as control [8] was co-incubated with the different LDL
preparations in MIN6 cells and preproinsulin mRNA levels were
quantified by real-time PCR experiments. Data are the mean ± SEM of
four independent experiments. b Effects of JNK inhibitor on the
activity of the (RIPE)3Luc construct. MIN6 cells were transiently
transfected with (RIPE)3Luc and co-cultured with LDL preparations
and 5 μmol/l of the JNK inhibitor (filled bars) or TAT (open bars) for
48 h. Luciferase activities were normalised using pRLSV40 renilla.
Each experiment was performed at least three times in triplicate. All
values are expressed as per cent of SV40Luc activity. Results are
expressed as mean ± SEM. ** p<0.01
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and prevented the reduction in Bcl2 expression induced by
oxidised LDL (Fig. 7b). In addition, HDL treatment
partially prevented the loss of preproinsulin mRNA and
promoter activity (Fig. 8a,b). The protective effects of HDL
on the activity of RipLuc were also observed at 48 h of
incubation (data not shown). HDL also efficiently pre-
vented oxidised LDL-induced AP1Luc activity (Fig. 9a)
and an increase in Fos expression in MIN6 cells (Fig. 9b)
and human isolated islets (Fig. 9c). The restoration of basal
activity of AP1 by HDL was already observable at 48 h
(data not shown). In line with the loss of AP1 activity,
HDL countered JNK’s effects on c-Jun phosphorylation
(Fig. 9d) and the decline in IB1 expression (Fig. 9e,f).
These data suggest that HDL exerts its protective action by
blocking the effects of oxidised LDL on the JNK signalling
pathway.
Discussion
Several studies have reported expression of receptors for
native and modified forms of LDL, including scavenger
receptor class B, member 1 and CD36 scavenger receptors,
as well as the uptake of these lipoproteins in pancreatic beta
cells [24, 28, 33, 42]. Herein, in agreement with a previous
study, we found that insulin-secreting cells cultured with
oxidised LDL have reduced preproinsulin gene expression
[24]. This perturbed expression was observed at protein and
mRNA levels, both in isolated human and rat islets and in
several insulin-secreting cell lines. The reduced luciferase
activity of RipLuc and the multimerised E elements-
containing promoter (RIPE)3Luc suggests that oxidised
LDL particles exert their action on the preproinsulin gene at
the transcriptional levels. This effect is mediated through
the E elements and is not the result of irreversible cell
damage as can be seen from the fact that mutation of these
elements prevents the changes in luciferase activity of
(RIPE)3Luc triggered by oxidised LDL. Several lines of
evidence support a role for c-Jun, a component of the AP1
transcriptional complex, in the decline of preproinsulin
gene transcription mediated by oxidised LDL [13]. Over-
expression of c-Jun has been shown to indirectly repress
the enhancer activity of the E elements by interfering with
the transactivating capacity of basic helix loop helix
transcription factors, which bind to the former element
[13, 14]. Conversely, induction of insulin expression is
accompanied by a decrease in c-Jun expression [43]. In line
with these observations, we found that the impaired
preproinsulin expression is associated with an increase in
AP1 transcriptional activity and c-Jun expression.
AP1 activity and c-Jun expression are induced by an
unusually broad range of environmental stressors [44].
Many of these stimuli activate JNKs, leading to enhanced
AP1 transcriptional activity. In cultured human fibroblasts
and human aortic endothelial cells, oxidised LDL has been
reported to increase the activity of AP1 and JNK,
respectively [25, 26, 45]. Moreover, activation of the JNK
pathway by overexpressing mitogen activated protein
kinase kinase kinase 1 in insulin-secreting cells reduces
the luciferase activity of (RIPE)3Luc [11]. For this reason,
we presumed that activation of JNK by oxidised LDL was
responsible for augmenting AP1 activity and therefore for
reducing preproinsulin gene expression. Consistent with
this, inhibition of JNK with JNK inhibitors prevented the
loss of (RIPE)3Luc activity and the decrease in preproinsu-
lin mRNA levels mediated by oxidised LDL. This finding
furnishes new evidence for the possible involvement of the
JNK pathway in impaired preproinsulin expression through
the E element.
Increased JNK activity and c-Jun expression have been
reported in many scenarios in which cells undergo
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Fig. 6 Analysis of IB1 levels. a The levels of IB1 in MIN6 cells
cultured at indicated times with 2 mmol/l LDL-cholesterol preparation
or vehicle (−) were assessed by western blotting. The results are
representative of three independent experiments. b, c The rate of
apoptosis was scored in MIN6 cells (grey bars) or isolated rat islets
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(JNKi). Each experiment was performed three times in triplicate.
Results are expressed as mean ± SEM. ** p<0.01. d Expression of Bcl2
was quantified by quantitative PCR. The mRNA level was normalised
against the housekeeping acidic ribosomal phosphoprotein P0 gene
(Rplp0) and expression levels from cells cultured with vehicle were set
to 100%. Data are the mean ± SEM of three independent experiments.
*** p<0.001
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apoptosis [46, 47]. As expected, oxidised LDL induced a
rise in the rate of apoptosis and JNK inhibitors protected
cells against this deleterious effect. The reduction of Bcl2
expression confirms activation of the apoptotic pathway
induced by oxidised LDL. In contrast, native LDL at
2 mmol/l cholesterol concentration did not induce apopto-
sis. This result is in agreement with previous studies
showing that native LDL-cholesterol at concentrations
lower than 3.1 mmol/l cholesterol does not cause apoptosis
[24, 28]. Some reports found no effects of oxidised LDL on
apoptosis [24, 33]. The discrepancy between the latter
studies and our data could be due to the length of exposure
to oxidised LDL. Indeed, we observed that 48 h incubation
with oxidised LDL is sufficient to initiate a slight decrease
in insulin levels but not to affect the rate of apoptosis (data
not shown). Thus, these data confirm that the loss of insulin
levels caused by oxidised LDL is not a consequence of cell
death and might precede the apoptotic events.
IB1 is a key modulator of the JNK pathway and is
required for cell survival and insulin expression [11, 15].
Long-term exposure of cells to proapoptotic stimuli
diminishes expression of Ib1 [15, 16]. Such a decrease
induces the JNK pathway and the subsequent activation of
AP1, thereby leading to impaired insulin synthesis and
increased apoptosis [11, 15, 16]. As expected, IB1 levels
were reduced in cells treated with oxidised LDL for
72 h. In contrast, these levels were unchanged after
45 min of treatment, although JNK activity occurred at
that time point. Therefore, the data show that the early
effects of oxidised LDL on induction of JNK activity do
not require downregulation of IB1. However, the latter
event can be responsible for maintaining prolonged acti-
vation of JNK.
In patients with diabetes and metabolic syndrome, low
serum HDL levels and elevated oxidised LDL concen-
trations are risk factors for the the development of
cardiovascular diseases [18–20]. While oxidised LDL has
pro-atherogenic effects, HDL is known to be anti-athero-
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Fig. 7 Protective effects of HDL against apoptosis mediated by
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1 mmol/l HDL-cholesterol (filled bar) or without (open bars). HDL
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Fig. 8 Protective effects of HDL on the loss of insulin levels induced
by oxidised LDL. a The preproinsulin mRNA levels were quantified
by real-time PCR experiments in cells incubated for 72 h in the
presence (filled bars) or absence (open bars) of 1 mmol/l of HDL and
2 mmol/l of LDL preparation. Results are expressed as the mean ±
SEM of at least three independent experiments measured in triplicate.
* p<0.05. b Transient transfection experiments were performed to
monitor the activity of RipLuc in cells incubated for 72 h in the
presence (closed bars) or absence (open bars) of 1 mmol/l of HDL
and 2 mmol/l of LDL preparation. Data (b) are expressed as fold
increase of RipLuc over the pGL3basic vector (Basic). All results are
expressed as the mean ± SEM of at least three independent experi-
ments measured in triplicate. *** p<0.001
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genic and cardioprotective. Besides its role in the reverse
transport of cholesterol, HDL has been shown in vitro to
exert its effects by inhibiting LDL oxidation and cell
signalling mediated by oxidised LDL; it also counters
several adverse biological effects, such as cytotoxicity and
inflammatory responses triggered by oxidised LDL [19, 48,
49]. In this report, we establish that HDL efficiently
counters the effects of oxidised LDL on apoptosis by
restoring expression of Bcl2. One possible mechanism is
the depletion by HDL of LDL from lipid peroxides through
enzymatic hydrolysis of phospholipid hydroperoxides, a
process effected by the HDL-bound enzyme paraoxonase.
This has been shown to reduce cytokine production
stimulated by oxidised LDL [50]. In addition, the idea that
HDL mediates its action by preventing activation of the
JNK pathway is supported by the fact that JNK and AP1
activities were not induced and that IB1 and FOS levels
were unaltered in cells co-cultured with oxidised LDL and
HDL. This hypothesis is supported by the fact that HDL
protects insulin-secreting cells from apoptosis induced by
VLDL [28]. As is the case here for oxidised LDL, VLDL-
mediated apoptosis was linked to impaired Ib1 expression
and an increase in JNK activity [28].
Our data also show that HDL exerted its effects on insulin
levels and AP1 activity as early as the 48-h time point. At that
incubation time, downregulation of Ib1 and apoptosis did not
occur. Thus, HDL counters the oxidised LDL-mediated
activation of JNK in a manner that is both dependent and
independent of IB1. More than 20 proteins are associated
with HDL. These include apolipoproteins that serve as
Fig. 9 HDL prevents induction
of the JNK pathway mediated
by oxidised LDL. a MIN6 cells
were transiently transfected with
the AP1Luc construct and incu-
bated with vehicle, native and
oxidised LDL with (closed bars)
or without (open bars) 1 mmol/l
HDL. b Fos mRNA levels
were measured in MIN6 cells
and (c) in human islets co-
cultured with LDL preparations
and with (filled bars) or without
(open bars) 1 mmol/l HDL-
cholesterol for 72 h. d JNK
activity was measured in whole-
protein extracts from MIN6 cells
cultured with vehicle (−), native
and oxidised LDL plus or minus
1 mmol/l HDL. e The effects of
HDL on Ib1 mRNA levels were
assessed in MIN6 cells and f in
human isolated islets exposed to
LDL preparations and HDL
(filled bars) for 72 h. The
mRNA level was normalised
against β-tubulin. Expression
levels from cells cultured with
native LDL were set to 100%.
Data in all panels are the
mean ± SEM of five independent
experiments. * p<0.05,
** p<0.01, *** p<0.001
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structural components, cofactors or inhibitors of enzymes, as
well as ligands of receptors. Future studies will have to clarify
which of these components mediate the protective effects of
HDL, which counter those of oxidised LDL, on beta cells.
Finally, this study highlights the biological consequences
and the relationship between the levels of the modified
lipoproteins and HDL for beta cell function. Reductions in
the concentration of HDL could potentiate the effects of
oxidised LDL, thereby contributing to beta cell dysfunc-
tion. Therefore, like hyperglycaemia and NEFA, modified
LDL could contribute to the development of diabetes. A
better understanding of the mechanisms underlying the
effects of oxidised LDL and HDL will help elucidate the
causes of human type 2 diabetes and may lead to novel
strategies for treatment or prevention of diabetes.
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